ArticleInfectious diseases and therapy2024

Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies.

Chris Wynne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.